Google+
background
Logo
Quintessence Biosciences, Inc.
3300 Commercial Avenue
Madison, Wisconsin 53714 USA
Phone: +1-608.441.2950
Fax: +1-608.441.2952
background
Main Image

 

Our Mission

Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.

 

Spotlight

Lead Candidate, QBI-139

A first in human Phase I trial of QBI-139 in cancer patients with solid tumors enrolled patients at the University of Wisconsin Comprehensive Cancer Center (UWCCC) in Madison and The University of Texas M. D. Anderson Cancer Center in Houston, Texas.

 

Information about the trial can be found at www.clinicaltrials.gov (Clinical Trials.gov Identifier: NCT00818831).

 

Upcoming Events

21-22 October 2014DLSS Entrepreneur Summit (Agenda) Quintessence Biosciences (QuintBio) will be attending the DLSS Summit in Milwaukee, Wisconsin.

3-5 November 2014BIOEurope (Agenda) Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the BIOEurope Partnering conference in Frankfurt Germany.

16-18 November 2014 Partnering for Cures (Program) Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the Partnering for Cures conference in New York City.

 

© 2014 Quintessence Biosciences, Inc. .
Home | About Us | Product Pipeline | Technology | News | Contact | Search